L-arginine in Treatment of Intrauterine Growth Restriction
NCT ID: NCT03321292
Last Updated: 2018-08-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
260 participants
INTERVENTIONAL
2017-10-15
2018-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Nitric oxide(NO) increases placental blood flow. So,it might be useful to improve IUGR pregnancy outcome .
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
L-Arginine Treatment for Severe Vascular Fetal Intrauterine Growth Restriction: a Randomized Double Bind Controlled Trial (L Arginine in IUGR)
NCT00549575
Arginine + Citrulline as a Supplement for Weight Gain in Fetus With a Decrease in Their Growth Curve
NCT05029778
L-Arginine in Pre-Eclampsia
NCT00157521
L-arginine Effects on Chronic Hypertension in Pregnancy
NCT00974714
Glomerular Injury of Preeclampsia
NCT00275158
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Patients in second group will receive Acetylesalicylic acid 75mg once daily. then follow up of both group by:
1. Daily fetal movement counting
2. Day after day CTG
3. Doppler twice weekly
4. Pelvic u/s weekly for:
A) Head circumference, Abdominal circumference, femur length B) Fetal weight C) Liquor amount: Amniotic Fluid Index Or MeanVertical Pocket
Decision of delivery will be determined when:
A) Fetal distress (non stress CTG) B) Mother starts labour C) Reversed umbilical artery Doppler.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
L-arginine and Acetylesalicylic acid
L-arginine 1000mg capsules( manufactured by Putriant Pride,INC Holbrook,NY 11741 U.S.A.) every 8 hours Acetylesalicylic acid 75 mg tablet(manufactured by Multi\_Apex Pharma , Egypt) once daily will be given for patients of group A starting from diagnosis till birth
L-arginine 1000 mg and Acetylesalicylic acid75mg
l-arginine 1000mg capsule will be given every 8 hours till delivery and acetylesalicylic acid75mg tablet once starting of diagnosis till birth.
Acetylesalicylic acid75mg
acetylsalicylic acid 75 mg tablet(manufactured by Multi\_Apex Pharma , Egypt) orally once daily will be given for patients of group B starting from diagnosis till birth
acetylsalicylic acid 75 mg
acetylsalicylic acid 75 mg will be given orally once daily for group B starting of diagnosis till birth.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
L-arginine 1000 mg and Acetylesalicylic acid75mg
l-arginine 1000mg capsule will be given every 8 hours till delivery and acetylesalicylic acid75mg tablet once starting of diagnosis till birth.
acetylsalicylic acid 75 mg
acetylsalicylic acid 75 mg will be given orally once daily for group B starting of diagnosis till birth.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Singleton pregnancy
* No maternal systemic disease
* No congenital fetal malformation
* Estimated fetal weight below 10th percentile
Exclusion Criteria
* Multiple pregnancy
* Maternal systemic disease
* Congenital fetal malformation
20 Years
40 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ain Shams University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hayam Fathy Mohammad
Assistant Professor of Obstetrics and Gynecology , Ain Shams University
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hayam FA Mohammad, MD
Role: PRINCIPAL_INVESTIGATOR
Ain Shams University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ain Shams University
Cairo, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Hayam Fathy Mohammad 2
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.